Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E23.07 EPS (ttm)3.54 Insider Own0.10% Shs Outstand1.48B Perf Week3.57%
Market Cap120.68B Forward P/E8.65 EPS next Y9.43 Insider Trans-15.90% Shs Float1.48B Perf Month3.72%
Income5.42B PEG3.00 EPS next Q2.20 Inst Own70.20% Short Float1.48% Perf Quarter3.61%
Sales32.65B P/S3.70 EPS this Y4.80% Inst Trans-2.46% Short Ratio3.84 Perf Half Y-10.86%
Book/sh-5.29 P/B- EPS next Y7.22% ROA8.70% Target Price89.73 Perf Year-23.19%
Cash/sh3.53 P/C23.08 EPS next 5Y7.69% ROE-94.50% 52W Range75.62 - 107.24 Perf YTD-11.50%
Dividend4.28 P/FCF16.90 EPS past 5Y7.60% ROI21.80% 52W High-23.92% Beta1.10
Dividend %5.25% Quick Ratio0.90 Sales past 5Y11.80% Gross Margin77.30% 52W Low7.89% ATR1.75
Employees30000 Current Ratio1.00 Sales Q/Q-1.30% Oper. Margin19.90% RSI (14)64.78 Volatility2.18% 2.12%
OptionableYes Debt/Eq- EPS Q/Q-5.10% Profit Margin16.30% Rel Volume0.74 Prev Close80.88
ShortableYes LT Debt/Eq- EarningsApr 25 BMO Payout113.20% Avg Volume5.68M Price81.59
Recom2.90 SMA203.42% SMA502.01% SMA200-5.26% Volume4,217,559 Change0.88%
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
May-22-19 09:50AM  Lilly's Crohn's Disease Candidate Meets Phase II Study Goals Zacks
09:23AM  3 Top Dividend Stocks With Yields Over 5% Motley Fool
08:47AM  Top Ranked Income Stocks to Buy for May 22nd Zacks
07:19AM  Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead Zacks
May-21-19 03:58PM  Top Marijuana Stocks That Pay Dividends Investopedia
09:00AM  Better Buy: AbbVie vs. Pfizer Motley Fool
08:00AM  AbbVie Launches ORILISSA (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
07:47AM  Top Ranked Income Stocks to Buy for May 21st Zacks
07:15AM  3 Top Dividend Stocks to Buy Right Now Motley Fool
May-20-19 12:31PM  Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch
09:02AM  AbbVie's Brain Cancer Candidate Fails in Phase III Study Zacks
May-19-19 07:00AM  Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big Motley Fool
May-17-19 05:19PM  Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL Zacks
09:19AM  AbbVie halts enrollment after brain cancer trial misses goal, shares fall Reuters
09:00AM  AbbVie halts patient enrollment after brain cancer trial misses goal Reuters
09:00AM  AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial MarketWatch
08:45AM  AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer PR Newswire
08:35AM  Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs Zacks
May-15-19 02:19PM  AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients PR Newswire
09:15AM  Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks
08:45AM  3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock Zacks
07:46AM  AbbVie Settles Humira Litigation With Boehringer Ingelheim Zacks
12:57AM  PRESS DIGEST -Wall Street Journal - May 15 Reuters
May-14-19 10:43AM  AbbVie Rises 3% Investing.com
10:13AM  MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System Business Wire
10:07AM  Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman MarketWatch
08:57AM  AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S. MarketWatch
08:34AM  AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim PR Newswire
08:00AM  AbbVie to Present at the UBS Global Healthcare Conference PR Newswire
May-13-19 06:00AM  AbbVie- Unique Mix of Growth, Yield and Value MoneyShow
May-09-19 01:39PM  Parnassus Endeavor Fund Buys 2 Pharmaceutical Stocks in 1st Quarter GuruFocus.com
May-08-19 04:49PM  Parnassus Endeavor Fund Buys AbbVie, Boosts Biogen GuruFocus.com
07:47AM  Top Ranked Income Stocks to Buy for May 8th Zacks
May-07-19 08:00AM  AbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference PR Newswire
May-06-19 09:21AM  The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo Zacks
09:11AM  Top Ranked Income Stocks to Buy for May 6th Zacks
06:37AM  Two Healthcare Stocks in the XLV Fund Stand Out InvestorPlace
06:30AM  Alector Announces First Alzheimers Disease Patient Dosed in Phase 1b Study of AL002 GlobeNewswire
May-03-19 11:37AM  Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates Zacks
06:10AM  Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod Zacks
May-02-19 01:21PM  These 6 biotech stocks are promising takeover targets MarketWatch
May-01-19 06:56PM  The Top Pharma Stocks for 2019 Investopedia
01:55PM  Profit from Earnings Volatility With This Biotech Stocks Pairs Trade InvestorPlace
08:55AM  The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products Zacks
Apr-30-19 02:52PM  Top Stock Reports for Facebook, Comcast & AbbVie Zacks
07:45AM  European Commission Approves SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis PR Newswire
07:08AM  AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting PR Newswire
Apr-29-19 05:08PM  Better Big Pharma Stock: AbbVie vs. AstraZeneca Motley Fool
09:15AM  Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks
09:00AM  AbbVie (ABBV) Upgraded to Buy: Here's Why Zacks
08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV) Zacks
07:59AM  Here are the biggest analyst calls of the day: Target, Disney, CVS, American Airlines, & more CNBC
Apr-28-19 09:00AM  Better Buy: Pfizer vs. AbbVie Motley Fool
Apr-27-19 01:00PM  Why AbbVie Is in Better Shape Than You Might Think Motley Fool
11:44AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
11:29AM  Biosimilar competition to AbbVies Humira is eroding profits, but company says it has confidence in pipeline MarketWatch
Apr-26-19 06:37PM  Edited Transcript of ABBV earnings conference call or presentation 25-Apr-19 1:00pm GMT Thomson Reuters StreetEvents
05:36PM  2 Large Drug Manufacturers Release 1st-Quarter Results GuruFocus.com
04:26PM  Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer Investor's Business Daily
08:00AM  3 Big Stock Charts for Friday: AbbVie, ConocoPhillips and MGM Resorts InvestorPlace
Apr-25-19 05:03PM  AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript Motley Fool
04:06PM  These Pharmas Beat First-Quarter Forecasts; But Biosimilars Rankled One Investor's Business Daily
03:57PM  AbbVie Climbs Earnings Beat, Guidance Boost TheStreet.com
02:00PM  What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings Motley Fool
11:56AM  AbbVie raises profit forecast, but Humira concerns weigh on shares Reuters
11:15AM  AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View Zacks
11:13AM  AbbVie Is Losing Its Humira Safety Blanket Bloomberg
10:04AM  AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters
08:50AM  AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up Zacks
08:34AM  AbbVie raises forecasts despite pressure on Humira Financial Times
08:08AM  AbbVie stock up 2% after earnings beat and raised outlook MarketWatch
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
07:52AM  AbbVie: 1Q Earnings Snapshot Associated Press
07:42AM  AbbVie Reports First-Quarter 2019 Financial Results PR Newswire
03:47AM  AbbVie Earnings, Revenue Beat in Q1 Investing.com
Apr-24-19 04:29PM  Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? Zacks
04:25PM  Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Zacks
04:13PM  AbbVie Expected to Earn $2.06 a share TheStreet.com
01:50PM  AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Heres what to expect MarketWatch
01:44PM  5 Turnaround Earnings Charts You Must See Zacks
11:40AM  Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales Zacks
11:31AM  Why Earnings Season Could Be Great for AbbVie (ABBV) Zacks
10:24AM  You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch
08:09AM  The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga
Apr-23-19 07:31PM  AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval Reuters
06:37PM  AbbVie stock ticks higher on FDA approval of psoriasis treatment MarketWatch
06:19PM  AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis PR Newswire
Apr-22-19 05:00PM  Better Buy: Biogen vs. AbbVie Motley Fool
10:33AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
08:15AM  AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect Motley Fool
Apr-20-19 08:00AM  3 Cancer Treatment Stocks to Buy in April Motley Fool
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
Apr-18-19 10:59AM  Can Q1 Earnings Lift Healthcare ETFs Higher? Zacks
10:33AM  AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? Zacks
10:22AM  Here Are the Key Takeaways From J&J's Q1 Earnings Report Zacks
10:04AM  Health Canada Approves SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis CNW Group
Apr-17-19 09:30AM  AbbVie Falls 3% Investing.com
Apr-16-19 09:28PM  Is TG Therapeutics a Buy? Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM